Albumin Paclitaxel Combined with Intrapleural Infusion of Bevacizumab + Lobaplatin for the Second-Line Treatment of Patients with Non-Squamous Non-Small Cell Lung Cancer

Table 4

Comparison of the quality of life scores between the two groups of patients (, points).

Scores		Treatment group (n = 62)	Control group (n = 64)	t
GH	Before	60.13 ± 4.36	59.56 ± 5.25	0.662	0.509
	After	66.25 ± 6.28	60.26 ± 7.16^#	4.986	<0.001
RP	Before	45.46 ± 5.08	46.14 ± 5.12	0.748	0.456
	After	58.28 ± 6.02	51.04 ± 6.16	6.670	<0.001
BP	Before	58.73 ± 4.76	59.01 ± 4.98	0.322	0.748
	After	68.08 ± 5.68	62.25 ± 6.11	5.543	<0.001
SF	Before	66.78 ± 7.14	65.05 ± 7.05	1.368	0.174
	After	73.28 ± 6.58	67.68 ± 6.08^#	4.964	<0.001
VT	Before	51.68 ± 6.06	52.28 ± 6.36	0.542	0.589
	After	63.28 ± 6.88	52.68 ± 6.62^#	8.814	<0.001

Compared with that before treatment of the group, , #.